Epitalon

• Short community courserecommended

  Community practice, not from a label or trial: low end of the 5-10 mg/day, 10-20 day range.

• Longer, upper-range community course

  Community practice, not from a label or trial: top of the stated range (10 mg/day for 20 days).

• Community practice, not from a label or trial: 5-10 mg/day subcutaneously, once daily, for 10-20 days, 1-2 cycles per year (Outliyr).
• Community practice, not from a label or trial: 'biohacker maintenance' 10 mg/day, often in the evening, 10-20 days, twice a year.
• Sublingual and nasal use (higher mg, 50-100 mg/day sublingual) is reported, but the source says no clinical data supports it; not encoded.

Route: Subcutaneous injection of a reconstituted lyophilized powder (community). The older human work was on epithalamin, the pineal extract, not synthetic epitalon (Outliyr).

Timing: Once daily, often evening (community).

• Lyophilized powder with bacteriostatic water; no sourced volume or storage temperature.
• The water in the protocols is arithmetic for a readable draw: a 10 mg vial in 1 mL gives 10 mg/mL, so 5 mg = 50 units and 10 mg = 100 units in a 100-unit syringe. Not a sourced instruction.

No reliable figure found in the sources; ask your prescriber or supplier.

1-2 courses per year (community), so roughly 26-52 weeks between courses.

Why:

• The weeks are derived from the stated 1-2 cycles per year; the source gives no explicit rest period.

• Never draw into the same syringe as another compound; use separate syringes and distinct injection sites.

Not FDA-approved. Registered or used in parts of the Russian medical system (Outliyr). Gray-market peptide in the US and EU; no quality oversight.

Common side effects:

• Injection-site redness and transient swelling; occasional mild fatigue (Outliyr; community reports, not trial data).

Stop and call your prescriber if:

• Injection-site infection
• New severe headache or neurological symptoms
• A theoretical cancer concern (telomerase/ALT activity) is raised but not shown to be harmful; avoid if pregnant, breastfeeding, under 18 or at high cancer risk without clinician oversight.

Labs and monitoring:

• No monitoring schedule was found in the sources.

No reliable source names a biomarker for this compound.

• Outliyr Epitalon report (community doses, regulatory status, safety, vial size)
• PubMed 12374906: Khavinson 2002 review of peptide bioregulators (abstract)